Cormatrix Cardiovascular
US-based CorMatrix develops biomaterial devices for body's self-repair of damaged heart tissues.
Founded
2001US-based CorMatrix develops biomaterial devices for body's self-repair of damaged heart tissues.
Founded in Roswell, United States, CorMatrix Cardiovascular is a pioneering medical device company dedicated to advancing cardiovascular health through innovative biomaterial devices. Their core mission is to harness the body's natural ability to repair damaged heart tissues, thereby improving patient outcomes and quality of life. The company's flagship product, CorPatch®, is an epicardial tissue support and repair device that acts as a decellularized extracellular matrix (ECM) scaffold. This product facilitates the migration and attachment of the patient's own cells to naturally support and rebuild weakened cardiac tissue.
CorMatrix has garnered attention from notable investors and medical professionals in the cardiovascular field. The company has achieved significant milestones, including regulatory approvals and successful clinical outcomes, positioning it as a leader in cardiovascular regeneration. Their innovative approach has had a profound impact on cardiac surgery, offering new hope for patients with damaged heart tissues and contributing to advancements in regenerative medicine.
Companies similar to Cormatrix Cardiovascular include Ventrix, Cormedics, Cardiovate and MedNews.
Cormatrix Cardiovascular was founded in 2001.
Cormatrix Cardiovascular's headquarters is located in Roswell, GA, US.
Cormatrix Cardiovascular's most recent funding round was for $1M (USD) in January 2015.
As of Jan 16, 2015, Cormatrix Cardiovascular has disclosed funding of $55.9M (USD). Undisclosed round amounts are excluded.
Cormatrix Cardiovascular has 75 employees as of Feb 5, 2024.
MedNews
